Clinical Trials

28 enrolled

Lymphoma, Mantle-Cell

NCT05100862 2026-04-22

MAHOGANY

780 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06839053 2026-04-22

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

30 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT06846671 2026-04-22

CaDAnCe-302

250 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06970743 2026-04-22

CaDAnCe-303

150 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03623373 2026-04-21

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Phase 2 Completed

13 enrolled 13 charts

Lymphoma, Mantle-Cell

NCT06337318 2026-04-21

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

600 enrolled

Classic Follicular Lymphoma

NCT00092222 2026-04-20

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

75 enrolled

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT02436707 2026-04-20

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

129 enrolled

Lymphoma

NCT04002947 2026-04-20

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

132 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04224493 2026-04-20

SYMPHONY-1

555 enrolled

Lymphoma, Follicular

NCT04404283 2026-04-20

ECHELON-3

239 enrolled 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05139017 2026-04-20

waveLINE-003

Phase 2/3 Recruiting

290 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-04-20

MK-2140-011

594 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04884035 2026-04-17

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Phase 1 Recruiting

224 enrolled

Lymphoma, B-Cell

NCT05888493 2026-04-17

LEDA

109 enrolled

Phase 1 Not yet recruiting

Lymphoma, Follicular, Recurrence

NCT07226843 2026-04-17

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

360 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

80 enrolled

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT05498220 2026-04-16

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Terminated

5 enrolled 13 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06522386 2026-04-16

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

50 enrolled

Lymphoma, Mantle-Cell

NCT06717347 2026-04-16

MK-2140-010

1,046 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07224100 2026-04-16

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

33 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01424982 2026-04-15

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

88 enrolled

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03856216 2026-04-15

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Phase 2 Terminated

15 enrolled 11 charts

Burkitt Lymphoma, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04978584 2026-04-15

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

62 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06561360 2026-04-15

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Other hematologic neoplasm

86 enrolled

Leukemia, Hairy Cell

NCT06651970 2026-04-15

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Phase 4 Recruiting

60 enrolled

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT06943872 2026-04-15

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

630 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

40 enrolled

Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT04799275 2026-04-14

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Phase 2/3 Suspended

422 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT05998642 2026-04-14

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

30 enrolled

Lymphoma, Non-Hodgkin

NCT06090539 2026-04-14

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

308 enrolled

Lymphoma, Non-Hodgkin

NCT06965114 2026-04-14

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Other hematologic neoplasm

84 enrolled

Leukemia, Hairy Cell

NCT01695941 2026-04-13

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

24 enrolled

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT01886872 2026-04-13

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

547 enrolled 19 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02160015 2026-04-13

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03220022 2026-04-13

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

46 enrolled 19 charts

Lymphoma, AIDS-Related

NCT03321643 2026-04-13

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

24 enrolled

Phase 2/3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03984448 2026-04-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

363 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04623541 2026-04-13

EPCORE™ CLL-1

195 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04840602 2026-04-13

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

92 enrolled

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05283720 2026-04-13

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06149286 2026-04-13

OLYMPIA-5

470 enrolled

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT06191744 2026-04-13

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT06564038 2026-04-13

Soundtrack-E

408 enrolled

Phase 1 Not yet recruiting

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT07444710 2026-04-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

16 enrolled

Phase 1/2 Not yet recruiting

Ann Arbor Stage II Mantle Cell Lymphoma

NCT07520006 2026-04-13

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

150 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04433156 2026-04-09

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Phase 2 Completed

26 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT01661881 2026-04-08

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

23 enrolled 8 charts